Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 09, 2026
TickeronGET DAILY SIGNALS
Why Is Tyra Biosciences (TYRA) Stock Down -27.38% Today?

Why Is Tyra Biosciences (TYRA) Stock Down -27.38% Today?

Key Takeaways

  • Shares plunged roughly 27.38% to about $19.41 in early trading, down from a prior close of $26.73.
  • Primary catalyst: Initial Phase 2 SURF302 efficacy data for lead candidate dabogratinib in intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC) came in below investor expectations.
  • Secondary driver: Wall Street characterized the readout as "lukewarm," prompting a sharp repricing of the stock's risk-reward.
  • Broader context: The move is company-specific rather than sector-wide, reflecting a binary clinical-data reaction typical of small- and mid-cap biotech names.
  • What traders are watching next: Management's decision on advancing dabogratinib into a registrational study and upcoming safety-sentinel cohort data.

Opening Summary

TYRA, the Nasdaq-listed shares of Tyra Biosciences, Inc., a clinical-stage biotechnology company developing next-generation precision medicines targeting fibroblast growth factor receptor (FGFR) biology, tumbled sharply in Tuesday's session. The stock fell approximately 27.38% to trade near $19.41, down from a previous close of $26.73. The sell-off was driven by the company's release of initial Phase 2 SURF302 data for dabogratinib, its lead oral drug candidate, which markets judged to be weaker than hoped despite a relatively clean safety profile.

Catalyst Breakdown: Phase 2 SURF302 Data Disappoints

The dominant force behind the decline was the first clinical readout from the SURF302 study, which is evaluating dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle-invasive bladder cancer. While the data demonstrated a favorable safety profile — with no Grade 4 or 5 treatment-emergent adverse events — the efficacy results left investors wanting more. Grade 3 treatment-emergent adverse events were reported in 14% of patients at the 60 mg dose and 9% at the 50 mg dose.

Tyra Biosciences reported a 100% overall response rate and a 75% best overall response complete-response (CR) rate in single-marker lesion patients at the 60 mg dose, which management said supports selection of that dose for a registrational adjuvant strategy. However, the market's reaction suggests many investors had positioned for stronger efficacy or cleaner differentiation, and the initial readout failed to clear that bar.

Analyst Reaction: "Lukewarm, but Not Program Terminating"

Sell-side commentary amplified the negative price action. Analysts described the initial efficacy data as lower than expected, characterizing the readout as "lukewarm, but not program terminating." The view on the Street is that, while a lower efficacy outcome was within the range of possibilities, the company still has room to fine-tune its approach — and that the fundamental thesis of an oral drug providing meaningful patient convenience remains intact. Even so, the cautious tone weighed on sentiment and drove a swift repricing of the shares.

Market Context and Trading Activity

The move in TYRA was overwhelmingly company-specific. Trading volume was sharply elevated relative to the stock's recent daily averages, consistent with a news-driven, high-conviction reaction to a binary clinical catalyst. The decline diverged from the broader biotechnology complex, which did not experience a comparable drawdown, underscoring that the sell-off was tied to the SURF302 readout rather than to sector or macro pressure.

From a technical standpoint, the shares gapped down through multiple recent levels of support, erasing much of the gains accumulated in the prior weeks as investors positioned ahead of the data. The stock had climbed roughly 13% in the week leading into the announcement, making it especially vulnerable to a disappointment-driven reversal.

What Comes Next for TYRA

Looking ahead, the key near-term focus for TYRA is whether management proceeds to advance dabogratinib into a registrational trial in IR NMIBC, a decision that will shape the program's long-term value. Investors will also be watching for the initial safety-sentinel cohort results from the BEACH301 study, including six-month annualized growth velocity and safety data across multiple dose levels, which the company has guided toward the end of the first quarter of 2027.

Risks remain pronounced. As a clinical-stage company with no approved products, TYRA is dependent on future data readouts and regulatory outcomes, and additional volatility around binary catalysts is likely. Broader financing, execution, and competitive dynamics in the FGFR and bladder-cancer spaces will also remain important factors for investors to monitor.

Trending AI Robots

For traders seeking a more systematic approach to navigating volatile, catalyst-driven stocks, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of approaches to consider. Explore the Trending AI Robots page to see which strategies are leading the market today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TYRA

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Aroon Indicator for TYRA shows an upward move is likely

TYRA's Aroon Indicator triggered a bullish signal on November 18, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator showed a similar pattern. In 190 of the 210 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TYRA's RSI Indicator exited the oversold zone, 20 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in 247 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

TYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TYRA as a result. In 86 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for TYRA turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 50 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

TYRA moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.112) is normal, around the industry mean (3.596). P/E Ratio (-8.849) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. TYRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
2656 State Street
Phone
+1 619 728-4760
Employees
87
Web
https://www.tyra.bio
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.